EMEA-001429-PIP01-13-M06
Table of contents
Key facts
| Invented name |
Besponsa
|
| Active substance |
Inotuzumab ozogamicin
|
| Therapeutic area |
|
| Decision number |
P/0398/2022
|
| PIP number |
EMEA-001429-PIP01-13-M06
|
| Pharmaceutical form(s) |
Powder for concentrate for solution for infusion
|
| Condition(s) / indication(s) |
Treatment of B cell acute lymphoblastic leukaemia
|
| Route(s) of administration |
Intravenous use
|
| Contact for public enquiries |
Pfizer Europe MA EEIG
Tel. +44 1304 6466 07 |
| Decision type |
PM: decision on the application for modification of an agreed PIP
|